The FDA has granted accelerated approval for a new indication for Wegovy (semaglutide) injection 2.4 mg: to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis). It is not approved for patients with cirrhosis of the liver. Developed by Novo Nordisk, Wegovy is the first GLP-1 drug approved to treat MASH. An ongoing study aims to confirm the clinical benefit of Wegovy in adults with MASH.

MASH — also called nonalcoholic steatohepatitis (NASH) — is a severe form of fatty liver disease. It affects between 1.5% and 6.5% of U.S. adults. The number of people in advanced stages of the disease is expected to double by 2030.

“If left untreated, MASH can lead to serious and potentially fatal outcomes. The clinical evidence s

See Full Page